CanCure, LLC
dba CanZx Biotherapeutics

Tel: (206) 353-7538
cancurellc@canzxbio.com

First-in-Class Cancer Immunotherapeutics


New Generation of Cancer-Immunotherapy:
Empower your own immune system to fight cancer

​  
Our goal is to make immunotherapy benefit the majority of cancer patients, not just a few

Jennifer Wu, PhD. President.
  

About CanCure

CanCure is drug development company dedicated to fighting cancer using novel strategies that harness the power of the human immune system. CanCure currently focuses on taking its leading product CuraB-10 into clinic in the very near future.
 
CuraB-10 is a first-in-class immune stimulatory monoclonal antibody targeting a tumor-released immune suppressive molecule soluble MHC I Chain-related molecule MIC (sMIC). In preclinical animal studies, CuraB-10 monotherapy effectively reduces tumor size and prolongs overall survival. CuraB-10 also enhances tumor response to immune checkpoint blocking therapies (nivolumab, pembrolizumab, and ipilimumab) when used in combination, and elicits a positive response even in tumors that failed to respond to these therapies.

Driven by innovation, CanCure technology is poised to change the landscape of cancer immunotherapy. 

About the Founder​​​​
Jennifer D. Wu, PhD, Professor
Founder and President
Dr. Wu is a leading global expert and visionary in the area of immuno-oncology. She has prior experience with biotechnology development and has previously served as Scientific Liaison and Section Director at several leading biotechnology companies. Dr. Wu was instrumental in securing NIH funding and achieving early development milestones for CanCure technologies. Dr. Wu is also currently a Professor at Northwestern University Feinberg school of Medicine and Robert H. Lurie Comprehensive Cancer Center.